Clinical trials: Stem Cell Transplants
Mediastinal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003941
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 222 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia, Lymphoma
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and…
- Conditions
- Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies
- Trial name
- NCT00801931
- Testing
- Alemtuzumab, Total Body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Central Nervous System Lymphoma
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
The purpose of this study is to test resting state functional Magnetic Resonance Imaging (rsfMRI) scans to see if rsfMRI scans are better than the standard task based fMRI scans at diagnosing or monitoring central nervous system…
- Trial name
- NCT03342586
- Testing
- Resting State fMRI (rsfMRI), Auditory Attention and Executive Functions Test, Memory Test
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
- Trial name
- NCT06903702
- Testing
- Azacitidine (AZA), Venetoclax, Allogeneic hematopoietic stem cell transplantation
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Multiple Myeloma
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the side effects of giving reduced-intensity conditioning followed by donor peripheral blood stem cell transplant (PBSCT) and how well it works in treating patients with multiple myeloma (MM).
- Trial name
- NCT00054353
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- 2 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Immune Mediated Anemia, Immune Mediated Thrombocytopenia
Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be.
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Trial name
- NCT05502783
- Testing
- fostamatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Non-Hodgkins Lymphoma
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.
- Trial name
- NCT00856245
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Thrombocytopenia, Stem Cell Transplant Complications
Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy
Isolated prolonged thrombocytopenia (PT) is a common complication after allogeneic stem cell transplantation with significant poor prognosis. No standard treatment is available.
- Trial name
- NCT03391856
- Testing
- N-acetyl-L-cysteine (NAC), supportive therapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University People's Hospital
Lymphoma
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
The goal of this clinical research study is to find the highest tolerable dose of vorinostat that can be given with gemcitabine, busulfan, and melphalan with a stem cell transplant.
- Trial name
- NCT01421173
- Testing
- Vorinostat, Gemcitabine, Busulfan
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Leukemia, MDS
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your…
- Trial name
- NCT04187105
- Testing
- Conditioning regimen with half-matched (haploidentical) stem cell transplant
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Illinois Chicago
Leukemia
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after a donor stem cell transplant may prevent the recurrence of Philadelphia…
- Trial name
- NCT00244829
- Testing
- imatinib mesylate, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Sickle Cell Disease, Sickle Cell Anemia
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
This is a study of patients with sickle cell disease. It aims to find out if people with sickle cell disease can be cured by changing their immune system before they have blood stem cell transplants.
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, SCD
- Trial name
- NCT02065596
- Testing
- Fludarabine, Hematopoietic Stem Cell Transplant (HSCT)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00255723
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Parkinson's Disease
Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease
This study is intended to look at the safety and efficacy of the use of autologous bone marrow derived stem cell transplant in patients with advanced Parkinson's disease.
- Trial name
- NCT00976430
- Testing
- Autologous Bone marrow derived stem cells transplant
- Where
- India
- Volunteers
- 5 people
- Sponsor
- Jaslok Hospital and Research Centre
Graft Versus Host Disease, Leukemia
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, together with antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00740467
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Paoli-Calmettes
Immunosuppression, Kidney Transplantation
HLA-Identical Sibling Renal Transplant Tolerance
The purpose of this study is to attempt to eliminate the necessity of immunosuppressive therapy for HLA-identical sibling Kidney Transplants, examine cellular chimerism of donor hematopoietic stem cell (DHSC) lineages for pairs…
- Conditions
- Immunosuppression, Kidney Transplantation, Graft Rejection
- Trial name
- NCT00619528
- Testing
- Infusion of Donor Hematopoietic Stem Cells and Campath-1H
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Hematopoietic Neoplasms (Leukemia, Lymphoma, Multiple Myeloma)
In Person and Mobile Health Coping Skills Training for Improving Symptom Management and Daily Steps in Hematopoietic Stem Cell Transplant Patients
The purpose of the study is to assess the feasibility, acceptability, and efficacy of a novel mHealth behavioral intervention to enable HCT patients to effectively cope with symptoms to improve their ability to engage in physical…
- Trial name
- CST Step Up (NCT03960619)
- Testing
- coping skills training
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Multiple Myeloma
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
This is an open-label, Phase II, single center trial of pembrolizumab (MK-3475), lenalidomide and dexamethasone in subjects with high risk Multiple Myeloma (hrMM) post high-dose chemotherapy with autologous stem cell…
- Trial name
- NCT02906332
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hackensack Meridian Health
Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II)
Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children
Hypothesis: Children diagnosed with a lysosomal disease will exhibit developmental, adaptive, and behavioral strengths and difficulties depending upon 1) biomedical risk factors (i.e.
- Conditions
- Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), Mucopolysaccharidosis Type III (MPS III), Mucopolysaccharidosis Type VI (MPS VI)
- Trial name
- NCT01938014
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Hematologic Diseases
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat…
- Trial name
- NCT04249830
- Testing
- Allogeneic Stem Cell Transplant, CliniMACS TCR α/β Reagent Kit and CliniMACS CD19
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Alice Bertaina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.